Neutralizing GP41 antibodies and their use

Patent metadata

Field	Value
Publication number	US-10047148-B2
Application number	US-201715699902-A
Country	US
Kind code	B2
Filing date	Sep 8, 2017
Priority date	Nov 7, 2011
Publication date	Aug 14, 2018
Grant date	Aug 14, 2018

Abstract

Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.

First claim

We claim:

1. A method of inhibiting an HIV-1 infection in a subject, comprising administering to the subject an effective amount of a monoclonal antibody, the monoclonal antibody comprising:
a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR)1, a HCDR2, and a HCDR3 comprising amino acids 26-33, 51-60, and 99-120 of SEQ ID NO: 1, respectively; and
a light chain variable region comprising a light chain complementarity determining region (LCDR)1, a LCDR2, and a LCDR3, comprising amino acids 26-31, 49-51, and 88-99 of SEQ ID NO: 2, respectively;
wherein the monoclonal antibody specifically binds gp41 and neutralizes HIV-1.

2. The method of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as one of SEQ ID NOs: 1, 3, 5, 149, 154, 189-192, 200-201, or 204, and further comprises at most ten amino acid substitutions in framework regions of the heavy chain variable region.

3. The method of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 11, wherein X 1 is Q or R, X 2 is V or A, X 3 is S or Y, and X 4 is T or I.

4. The method of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as one of SEQ ID NOs: 1, 3, 5, 149, 154, 189-192, 200-201, or 204.

5. The method of claim 1 , wherein the light chain variable region comprises the amino acid sequence set forth as one of SEQ ID NOs: 2, 4, 150-152, or 164-168, and further comprises at most ten amino acid substitutions in framework regions of the light chain variable region.

6. The method of claim 1 , wherein the light chain variable region comprises the amino acid sequence set forth as one of SEQ ID NOs: 2, 4, 150-152, or 164-168.

7. The method of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as one of SEQ ID NOs: 1, 3, 5, 149, 154, 189-192, 200-201, or 204, and the light chain variable region comprises the amino acid sequence set forth as one of SEQ ID NOs: 2, 4, 150-152, or 164-168.

8. The method of claim 1 , wherein:
the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 154, and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 152; or
the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 192, and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 152.

9. The method of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1.

10. The method of claim 1 , wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2.

11. The method of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1 and further comprises at most ten amino acid substitutions in framework regions of the heavy chain variable region, and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2 and further comprises at most ten amino acid substitutions in framework regions of the light chain variable region.

12. The method of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1, and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2.

13. The method of claim 1 , wherein the antibody is an IgG, IgM or IgA.

14. The method of claim 1 , wherein the antibody neutralizes at least 98% of the HIV-1 isolates listed in FIGS. 17C-17F with an inhibitory concentration (IC50) of less than 50 μg/ml.

15. The method of claim 1 , wherein the antibody is a bispecific antibody.

16. The method of claim 1 , wherein the method is a method for treating an HIV-1 infection, and wherein the subject has acquired immune deficiency syndrome (AIDS).

17. The method of claim 1 , further comprising administering to the subject an additional anti-viral agent.

18. The method of claim 17 , wherein the additional antiviral agent comprises a nucleoside analog reverse-transcriptase inhibitor, a nucleotide reverse transcriptase inhibitor, a non-nucleoside reverse transcriptase inhibitor, a protease inhibitor, an entry or fusion inhibitor, a maturation inhibitor, or a broad spectrum inhibitor or a combination thereof.

19. The method of claim 1 , further comprising administering to the subject one or more additional antibodies, wherein the additional antibodies specifically bind to gp120 and/or gp41 and neutralize HIV-1.

20. A method of inhibiting HIV-1 infection in a subject, comprising administering to the subject an effective amount of an antigen binding fragment of a monoclonal antibody, the antigen binding fragment comprising:
a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR)1, a HCDR2, and a HCDR3 comprising amino acids 26-33, 51-60, and 99-120 of SEQ ID NO: 1, respectively; and
a light chain variable region comprising a light chain complementarity determining region (LCDR)1, a LCDR2, and a LCDR3, comprising amino acids 26-31, 49-51, and 88-99 of SEQ ID NO: 2, respectively;
wherein the antigen binding fragment specifically binds gp41 and neutralizes HIV-1.

21. The method of claim 20 , wherein the antigen binding fragment is a Fab fragment, a Fab′ fragment, a F(ab)′2 fragment, a single chain Fv protein (scFv), or a disulfide stabilized Fv protein (dsFv).

22. The method of claim 20 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1.

23. The method of claim 20 , wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2.

24. The method of claim 20 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1 and further comprises at most ten amino acid substitutions in framework regions of the heavy chain variable region, and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2 and further comprises at most ten amino acid substitutions in framework regions of the light chain variable region.

25. The method of claim 20 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1, and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2.

Assignees

• Us Health

Inventors

• Connors Mark
• Huang Jinghe
• Laub Leo B
• Kwong Peter
• Nabel Gary
• Mascola John R
• Zhang Baoshan
• Rudicell Rebecca S
• Georgiev Ivelin
• Yang Yongping
• Zhu Jiang
• Ofek Gilad

Classifications

• A61P31/18

  for HIV · CPC title

• C07K16/114

  Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV] · CPC title

• C07K16/1145 Primary

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• C07K2317/14

  Specific host cells or culture conditions, e.g. components, pH or temperature · CPC title

• G01N33/56988

  HIV or HTLV · CPC title